Effect of donor-to-recipient HLA matching in low-immunological risk kidney transplant recipients without induction therapy on acute rejection, graft survival, infections, and surgical complications at 3 years: The road towards new recommendations

• Published in: Transplant immunology Vol. 69; p. 101490
• Main Authors: Abou-Jaoudé, Maroun, El Hage, Said, Akiki, Dany, Araman, Rita
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.12.2021
• Subjects: Acute rejection; Adult; Graft Rejection; Graft Survival; HLA Antigens; HLA matching; Humans; Induction Chemotherapy; Induction therapy; Kidney Transplantation; Low-immunological risk; Retrospective Studies; HLA matching; A; CTS; C; PS; NS; F; KTR; N; P; SD; R; DSA; ANZDATA; IL2-RA; USRDS; FSGS; Hb; UNOS; ETKAS; Acute rejection; Graft survival; DGF; Tx; Low-immunological risk; CI; KT; CNIs; GS; CMV; AR; ATG; Induction therapy; KDIGO; HLA; PRA; Kidney transplantation
• ISSN: 0966-3274; 1878-5492
• DOI: 10.1016/j.trim.2021.101490

Donor-to-recipient human leukocyte antigen mismatching is considered one of the strongest determinants for graft and patient survival in kidney transplant recipients (KTR). This retrospective study discusses the impact of HLA matching as low immunological risk KTR without induction therapy. Records of 80 adult kidney transplant patients were reviewed with three years of the follow-up. All patients had panel reactive antibodies (PRA) < 20%, absence of donor-specific antibodies (DSA) and did not receive the induction therapy. These patients were divided into two groups according to their HLA matching between donor and recipient: 55 patients with ≥ 3 HLA matches (Group I; low immunogenicity) were compared to 25 patients with <3 HLA matches (Group II; high immunogenicity). The primary endpoints included the rate and severity of acute rejection (AR) episodes, graft function (creatinine level), and survival at 1, 3, 6, 12, and 36 months. Secondary endpoints include the rate and type of infections at one-year, surgical complications at one-year, and patient survival at 1, 6, 12, and 36 months after kidney transplantation. Baseline demographic characteristics were comparable between the two groups except for recipient age, donor gender, and pre-transplant dialysis time. There was no significant difference observed between two groups at one-year in infection rate, the length of hospital stay, AR severity, the rate of cytomegalovirus infection, and the occurrence of delayed graft function. However, the rate of AR, the graft function upon discharge, and the rate and type of surgical complications at one-year were significantly higher in Group II (high immunogenicity). The patient and graft survival at three years, the death-censored graft survival, and the serum creatinine levels at 1, 3, 6, 12, and 36 months were similar between two groups. Two deaths occurred in each group (NS). In our center, the donor-to-recipient HLA mismatch is not considered an immunological risk factor in low-risk kidney transplant recipients (PRA < 20% and absence of DSA). •HLA mismatch is no more an immunological risk factor in low-risk KTRs without induction therapy and should not delay KT.•Patient and graft survival at three years, death-censored graft survival, and serum creatinine levels were similar.•Literature considers mismatched HLAbetween donor and recipient an immunological risk factor. Thus, induction should be used.•Low-immunological risk KTRs were divided into HLA-matched and HLA-mismatched patients and followed-up.